Mr. George Achilleos reports

NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS

Netramark Holdings Inc. has released the voting results from its annual general and special meeting of shareholders, held on March 28, 2024.

Shareholders voted in favour of all matters of business before the meeting. Each of those matters is set out in detail in the management information circular dated Feb. 16, 2024, and published in connection with the meeting, which is available on the company's website.

Shareholders voted in favour of reappointing MNP LLP as auditor of the company, setting the number of directors at five, and also approved the company's amended and restated stock option plan and amended and restated equity incentive plan.

Shareholders overwhelmingly approved the nominees to the board of directors. The returning members of the board are Kevin Taylor, Sheetal Jaitly, Andrew Parks and Joseph Geraci. George Achilleos was added as a new member of the board replacing Gino DeMichele, who did not stand for re-election and as of March 28, 2024, has ceased to be a director of the company.

"As a founder of the public entity which is Netramark Holdings Inc., I am extremely proud of what we have achieved but even more excited about our future," said Mr. DeMichele. "We are at the forefront of introducing innovation into foundational aspects of a clinical trial, which can have a long lasting impact on the pharmaceutical industry. Our technology not only continues to deliver meaningful insights, which historically have not been easily exposed, but to also deliver the insights in weeks. I have enjoyed working closely with the board of directors and the management team and look forward to continuing in an advisory role."

"I want to express my appreciation to Gino for his contributions, he has been an integral part of the team and I look forward to our continued relationship, as we have much more to accomplish as a company," said Mr. Achilleos, Netramark chief executive officer.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence/machine learning solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.